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ABSTRACT
Introduction: The influence of n-3 long-chain
polyunsaturated fatty acids (LCPUFA) supplementation
on brain functioning is debated. Some studies have
found positive effects on cognition in children with
learning difficulties, elderly people with cognitive
impairment and depression scores in depressed
individuals. Other studies have found null or negative
effects. Observational studies in adolescents have
found positive associations between fish consumption
(containing n-3 LCPUFAs) and academic achievement.
However, intervention studies in typically developing
adolescents are missing.
Objective: The goal of this study is to determine the
influence of increasing Omega-3 Index on cognitive
functioning, academic achievement and mental well-
being of typically developing adolescents.
Methods and data analysis: Double-blind,
randomised, placebo controlled intervention; 264
adolescents (age 13–15 years) attending lower general
secondary education started daily supplementation of
400 mg eicosapentaenoic acid and docosahexaenoic
acid (EPA+DHA) in cohort I (n=130) and 800 mg EPA
+DHA in cohort II (n=134) or a placebo for 52 weeks.
Recruitment took place according to a low Omega-3
Index (<5%). The Omega-3 Index was monitored via a
finger prick at baseline and after 3, 6 and 12 months.
The supplement dose was adjusted after 3 months
(placebo analogously) to reach an Omega-3 Index of
8–11%. At baseline, 6 and 12 months, a
neuropsychological test battery, a number of
questionnaires and a standardised math test (baseline
and 12 months) were administered. School grades
were collected. In a subsample, sleep quality and
quantity data (n=64) and/or eye-tracking data (n=33)
were collected.
Ethics and dissemination: Food2Learn is
performed according to Good Clinical Practice. All data
collected are linked to participant number only. The
results will be disseminated on group level to
participants and schools. The results will be presented
at conferences and published in peer-reviewed
journals. The study is approved by the Medical Ethical
Committee of Atrium-Orbis-Zuyd Hospital and is
registered at the Netherlands Trial Register (NTR4082).
Trial registration numbers: NTR4082 and
NCT02240264; Pre-results.
INTRODUCTION
There is a debate whether long-chain polyun-
saturated fatty acids (LCPUFA) improve cog-
nitive performance. LCPUFAs from the n-3
family such as docosahexaenoic acid (DHA,
22:6n-3) and eicosapentaenoic acid (EPA,
20:5n-3) are involved in many aspects of
brain functioning, for example, neuronal
membrane ﬂuidity and neurotransmission.1 2
There is evidence that consumption of
Omega-3 LCPUFAs plays a protective role in
age-related cognitive decline3 and
Alzheimer’s disease.4 In premature babies, it
Strengths and limitations of this study
▪ Only known randomised controlled trial investi-
gating the effect of increasing Omega-3 Index
with krill oil supplementation on learning, cogni-
tion, behaviour and visual processing in typically
developing adolescents.
▪ First known study to select participants based on
a low Omega-3 Index and includes a persona-
lised dose adjustment based on the Omega-3
Index after 3 months of intervention.
▪ Data on depression, self-esteem and motivation
are obtained via self-reported questionnaires,
which might increase the risk for systematic
bias.
▪ Owing to practical constraints, it was not pos-
sible to completely standardise the test proced-
ure (eg, meal before the testing session and the
time of testing); this could influence test results.
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has been shown that higher Omega-3 LCPUFAs con-
sumption is associated with advanced cognitive develop-
ment.5 Furthermore, in children, it might lead to
improvement of symptoms associated with autism and
attention deﬁcit hyperactivity disorder (ADHD).6
Although previous research is not conclusive, it does
suggest that in certain sensitive periods Omega-3
LCPUFAs might contribute to optimising cognitive per-
formance and/or cognitive development.
Adolescence has received limited attention in studies
on n-3 LCPUFAs. The brain and prefrontal cortex con-
tinue to develop until the late 20s.7–11 It is thus crucial
to study the role of Omega-3 LCPUFA in adolescence as
they play an important role in brain development and
functioning. For example, DHA is an important struc-
tural component of the neural cell membrane, inﬂuen-
cing membrane ﬂuidity and signal transduction.12 13
Moreover, higher DHA intake has been associated with
changes in the functional activity of the prefrontal
cortex in boys aged 8–10 years.14 Even though EPA is
only present in very small amounts in the brain,15 it is
also involved in important brain processes such as
neurite outgrowth, regulation of gene expression and in
anti-inﬂammatory, antithrombotic and vasodilatory pro-
cesses which might assist brain functioning.15
Studies on the relationship between measured
LCPUFA status or supplementation and cognitive func-
tioning in adolescents are, to the best of our knowledge,
not available. Observational studies investigating the
association between ﬁsh intake and cognitive function-
ing in adolescents are, however, available. Kim et al16
showed that adolescents aged 15 years who regularly
consumed ﬁsh had signiﬁcantly better academic per-
formance than their non-ﬁsh consuming or less ﬁsh con-
suming peers. Åberg et al17 demonstrated that high ﬁsh
consumption in boys at age 15 years was associated with
better cognitive performance at age 18 years. Finally, de
Groot et al18 studied 700 adolescents aged 12–18 years
for whom ﬁsh consumption data, end-term grades (for
Dutch, English and Math) and score on the Amsterdam
Vocabulary Test was collected. Contrast analyses demon-
strated a u-shape association between ﬁsh consumption
and vocabulary (p=0.01) and a nearly signiﬁcant associ-
ation with average end-term grades (p=0.07). Thus,
higher ﬁsh intake was associated with more advanced
vocabulary and an almost signiﬁcant higher average
end-term grade. However, eating more ﬁsh than the
recommended amount (>2 ﬁsh portion/week) was not
associated with a beneﬁcial outcome.
Studies looking at the measured LCPUFA status and
depression in typically developing adolescents are also
limited. We are only aware of the study by Mamalakis
that showed a negative association between EPA mea-
sured in adipose tissue and score on the Beck
Depression Inventory (ie, higher EPA, fewer depressive
symptoms). Furthermore, a positive association between
dihomogamma linolenic acid (DGLA, C20:3n-6) mea-
sured in adipose tissue and score on the Centre for
Epidemiologic Studies Depression Scale (CES-D)
(ie, higher DGLA, more depressive symptoms) was
shown.19 This was, however, only true after correction
for adiponectin. Although self-esteem has often been
associated with depression,20 we found no studies taking
self-esteem into account when studying the association
between LCPUFA and depression in adolescents.
While observational studies point to a beneﬁcial asso-
ciation between ﬁsh intake (the main source of DHA
and EPA) and school grades in adolescents and since
causality cannot be proven by observational studies,
intervention studies are needed. Furthermore, little is
known about the effects of Omega-3 fatty acids on
depression and self-esteem in typically developing
adolescents.
This paper describes the design of Food2Learn, a
double-blind, randomised, placebo controlled interven-
tion in which the inﬂuence of an increase in the
Omega-3 Index with 1-year of krill oil supplementation
on cognition, academic achievement and behaviour in
typically developing adolescents is investigated. In addi-
tion, we try to counteract design issues such as bioavail-
ability, baseline Omega-3 Index and study population
which could have caused neutral results in earlier
trials.21
Bioavailability
The bioavailability of DHA and EPA depends mostly on
the form in which they are bound and the food matrix
with which the DHA and EPA are taken. Most previous
trials have chosen unemulsiﬁed ethyl-ester or triglycer-
ides and have advised participants to consume capsules
with breakfast, both of which lead to lower absorption of
the LCPUFAs.21–23 In Food2Learn, krill oil is used as
supplementation. Krill oil contains 30–65% of the EPA
and DHA in the phospholipid form. Phospholipids have
amphiphilic properties and therefore emulsifying prop-
erties that enhance absorption24–26 and are also better
absorbed by the brain than triglycerides.27 Another
factor important for DHA and EPA absorption is the
presence of fat in the meal. Some studies report a trifold
higher LCPUFA absorption when LCPUFA capsules are
taken with a high fat meal, compared to a low fat
meal.23 This is hypothesised to be caused by the stimu-
lating effect of fat on pancreatic lipase.22 Therefore, par-
ticipants in Food2Learn are asked to consume the
capsules with dinner, the fattiest meal of the day.28
BASELINE OMEGA-3 INDEX
In earlier studies, participants were often recruited
without researchers knowing the baseline Omega-3 fatty
acid status of participants. This has led to participants
with a wide range in statuses being included, while one
can expect that effects of supplementation are more
likely in participants with a low Omega-3 fatty acid status.
This wide range in statuses can lead to similar end
Omega-3 statuses in the placebo and treatment groups
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and thus similar outcome measures. To increase the
chance of observing any effects of supplementation, par-
ticipants for Food2Learn are recruited on the basis of a
low Omega-3 Index (<5%).29 The Omega-3 Index is
deﬁned as EPA plus DHA in erythrocytes and is based
on a standardised analytical method.21 Additionally, to
counteract interpersonal variability in the uptake/
metabolism of the LCPUFA supplementation, a dose
adjustment based on the individual Omega-3 Index
blood levels after 3 months of supplementation was
applied. This dose adjustment should ensure that parti-
cipants in the active treatment group achieve the
target range of 8–11%. This target range is an estimate
based on the Omega-3 Index associated with the lowest
mortality risk in coronary heart disease.29
STUDY POPULATION
Richardson showed that LCPUFA supplementation was
especially beneﬁcial in the 20% lowest performing chil-
dren.30 In the Netherlands, secondary education is
divided into three levels: preuniversity, higher general
and lower general secondary education (LGSE).
Approximately 38% of all adolescents attend LGSE.31
LGSE is further divided into four sublevels. For the
current study, students from the highest sublevel, the
theoretical learning pathway (TLP), were recruited.
Approximately 40% of students attending LGSE are in
the TLP.
Objective and hypotheses
The primary objective of Food2Learn is to study the
effect of an increase in the Omega-3 Index due to 1-year
of krill oil supplementation in 13–15 year-old typically
developing adolescents from LGSE on cognitive per-
formance. The secondary objective is to study the effect
of an increase in the Omega-3 Index due to 1 year of
krill oil supplementation in 13–15 year-old typically
developing adolescents from LGSE on academic achieve-
ment and behaviour. Furthermore, the relationship
between Omega-3 Index and cognitive performance,
academic achievement and behaviour in typically dev-
eloping adolescents will be further explored. The
hypothesis is that 1 year krill oil supplementation and a
higher Omega-3 Index will lead to improved cognition,
academic achievement scores and behaviour scores in
typically developing Dutch adolescents attending the
LGSE. The third objective is to study the effect of an
increase in the Omega-3 Index due to 1 year of krill oil
supplementation in 13–15-year-old typically developing
adolescents from LGSE on sleep quality and quantity,
and visual processing.
METHODS
Study design
Food2Learn is a double-blind, randomised, placebo-
controlled trial, with repeated measurements (at base-
line, 3 months, 6 months and 12 months) to study the
effect of an increase in the Omega-3 Index due to 1-year
of krill oil supplementation on cognitive performance,
academic achievement and behaviour of second year
LGSE students. Informed consent was obtained from all
participants and their parent(s) and/or guardian(s).
This trial is registered at The Netherlands Trial Register
(NTR4082) and at ClinicalTrials.gov (NCT02240264).
The Items from the WHO Trial Registration Data Set
can be found in the online supplementary ﬁles.
Participants
Inclusion and exclusion criteria
All second year students attending high school at the
LGSE TLP level with a baseline Omega-3 Index <5%
were eligible to participate in the study. Students were
excluded if they had (1) a baseline Omega-3 Index of
>5%, (2) an allergy to ﬁsh or shellﬁsh or (3)
haemophilia.
Determination of participation
Participants could discontinue participation at any time
during the study. If a participant indicated that he/she
wished to stop supplementation, the reason for discon-
tinuation was asked and the participant was asked to
continue with the test sessions according to the inten-
tion to treat principle, but both were voluntary.
Recruitment and screening
One hundred and twenty-three schools in the southern
provinces of the Netherlands were contacted to partici-
pate in Food2Learn. Eventually, 19 school boards gave
approval. The target group was then approached in a
classroom setting. A video explaining the study was
shown, the capsules and the ﬁnger prick were shown,
and any questions were answered. Students received an
information letter and were asked to discuss the study
with their parents. If requested, a voluntary additional
information evening was held.
If the student wanted to participate, the informed
consent form had to be signed by the student and
parent(s) and/or guardian(s) and handed in to the
researchers at site. All students who handed in an
informed consent form received a ﬁnger prick to
determine the Omega-3 Index; no other prescreening
methods were used. If the participant completed the
whole study, he/she received a voucher for the
cinema. In cohort I of Food2Learn, the needed
number of participants was not enrolled; therefore, a
second cohort was added to the study. Currently,
cohort II is in progress.
Randomisation and blinding
On entry, participants received a participant number. An
independent researcher was responsible for treatment
allocation. The participants were stratiﬁed by sex and
were randomly allocated to the placebo or krill oil group
by an independent researcher. Equal numbers of partici-
pants were randomised to the active treatment and the
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placebo groups. The group allocation sequence was
computer generated and executed by an independent
researcher. Researchers at site were only told which box
number had to be given to which participant number
and were not aware how boxes were divided over
placebo/krill oil group. To prevent the risk of unblind-
ing, each participant received a personalised box with
capsules. The packaging and the capsules themselves
were identical for the active treatment and placebo
groups. The capsules were coloured black to hide the
redness of krill oil. Furthermore, a vanilla odour was
added to hide any possible ﬁshy smell/taste. Neither the
researchers at the site nor the participants were
informed of group allocation prior to the completion of
the whole study (cohorts I and II). Preliminary unblind-
ing of the trial was to be executed only by an independ-
ent researcher in the case of severe adverse effects.
Procedure—baseline
Before starting supplementation, participants underwent
a neuropsychological test battery, ﬁlled out question-
naires and performed a standardised math test (see
outcome measure, ﬁgure 1 and table 1); these tests were
executed at school in a classroom setting. Three cogni-
tive tests were administered in a group setting (10 stu-
dents max): The Letter Digit Substitution Test (LDST),
D2 test of Attention (D2) and Digit Span Forward (DSF)
and Backward (DSB). These tests were led by one
researcher via a standardised protocol, while one or two
other researchers (depending on group size) made sure
that participants understood the tests and complied with
the protocol. All tests were ﬁrst explained and a practice
version was always completed by the participants. After
this group test session, all participants ﬁlled out the
questionnaires individually, during which participants
were called one by one to perform the Stroop Test and
Concept Shifting Test (CST) individually under supervi-
sion of one researcher. After data collection, participants
completed a standardised computerised math test, in
silence, in a classroom setting.
Procedure—3 months follow-up
After 3 months of supplementation, participants again
received a ﬁnger prick to determine the Omega-3
Index. Blood analyses and dose adjustments were exe-
cuted by a researcher who was not actively involved in
the study. When the increase in the Omega-3 Index in a
participant of the active group was insufﬁcient, the sup-
plementation dose was adjusted in this participant and
in one participant in the control group with the same
number of capsules. This was carried out to ensure
blinding of the researchers. However, the Omega-3
Indexes of the participants of cohort I were found to be
signiﬁcantly lower than the target range at 3 months.
Therefore, it was decided that the dose of all partici-
pants would be increased to eight capsules per day.
Furthermore, it was decided to increase the starting
dose of the cohort II to eight capsules per day to ensure
that the target range would be achieved.
Procedure—6 months and 12 months follow-up
The procedure completed at baseline was repeated
again after 6 months. This process was again repeated
after 12 months of intervention. The standardised math
test was only completed at baseline and after 12 months
(for an overview, see ﬁgure 1).
Intervention
After baseline neuropsychological testing, participants
started with supplementation. The krill oil contained at
least 40 g phospholipids per 100 g krill oil. The fatty acid
proﬁle of these phospholipids was at least 14 g EPA and
6 g DHA. The remaining composition of krill oil was
mainly triglycerides (32%), free fatty acids (6–7%) and
small amounts of cholesterol, cholesterol esters, ash and
a trace amount of astaxanthin (80 µg/100 g). One krill
oil capsule contained a total of 0.5 g krill oil, which sup-
plied 65 mg EPA and 35 mg DHA. For the placebo cap-
sules, a fatty acid mixture was chosen that reﬂects the
fatty acid composition of the average European diet
(26.0% C16:0, 4.6% C18:0, 35.8% C18: 1–9, 16.7%
Figure 1 Timeline of study. Neuropsychological tests (NPT) are at all time points equal namely: the letter digit substitution test,
D2 test of attention, digit span forward and backward, Concept Shifting Test and Stroop Test. 1Eye tracking was performed in a
subsample of participants. 2Sleep was measured in a subsample of participants in the second cohort with a combination of
ActivPAL accelerometer data, questionnaires and a self-reported sleep diary. 3To determine Apoe status saliva was collected.
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C18:2–6, 2.1% C18:3–3, 0% C20:4–6 and 14.8% other
compounds).32 The placebo contained a mix of olive
oil, corn oil, palm oil and medium chain triglycerides in
the following ratio 4:4:9:3. The placebo contained no
marine n-3 fatty acids.
In cohort I, participants were instructed to start with an
intake of four capsules per day containing in total 260 mg
EPA and 140 mg DHA, almost the daily recommended
amount of 450 mg of EPA/DHA per day as set by the
Dutch health council.33 In cohort II, the starting dose was
increased to eight capsules, as cohort I showed that the
initial dose of 400 mg DHA+EPA did not lead to a sufﬁ-
cient increase in the Omega-3 Index. Eight capsules
provide 520 mg EPA and 280 mg DHA per day. To increase
adherence to the protocol, participants could receive a
daily text message reminder. Furthermore, participants
who had an insufﬁcient increase in their blood Omega-3
Index after 3 months of supplementation and an equal
number of participants from the placebo, as noted by the
independent researcher, received a phone call to try to
increase compliance. Participants were asked to return all
left-over capsules at the end of the study or when they
decided to drop out, so compliance could be calculated
on the basis of the number of capsules returned.
Outcome measures—cognitive performance measurements
The cognitive tests were selected on the basis of their
usability as determined in other studies with adoles-
cents;18 reference scores are thus available. These tests
have also previously been shown to increase activation of
the frontal cortex, the area of the brain associated with
the accumulation of DHA,14 furthermore the prefrontal
cortex is the brain area most in development during
adolescence.9 Tests used were: the LDST to measure
speed of information processing, D2 as a measure for
selective attention, DSF and DSB as measures of short-
term memory and working memory, CST as a measure
for cognitive shifting and Stroop task as a measure for
cognitive inhibition. For an explanation of the tests, see
online supplementary appendix A.
Academic achievement
Math test
All students complete a standardised math test at base-
line and at the end of the study. This math test is based
on the end terms as set by the Dutch government. The
test is computer-based and participants have to take the
test without a calculator.34
School performance
All schools provide school grades (ranging from 1.0=very
bad to 10.0=excellent) of participants for the subjects
Dutch, English and Mathematics. These subjects are
chosen as they are considered core subjects and are
therefore compulsory for all students.
Behaviour measurements
Absenteeism
Schools provide the number of hours the participants
were absent and the reason for absence.
Motivation
The Motivated Strategies for Learning Questionnaire
consists of two parts: a motivation part and a learning
strategies part.35 In this study, only the motivation part is
used. The motivation section assesses student goals and
value beliefs concerning school, their beliefs about their
skills to succeed in school and their test anxiety. The
internal consistency for the section measuring motiv-
ation is very good (α between 0.62 and 0.93).36
Table 1 Questions and questionnaires at different time points
Question/questionnaire Before Baseline 3 months 6 months 12 months
Weight X
Length X
Level of parental education X
Nationality X
Country of birth X
Language spoken at home X
School carrier (focus chosen, skipping or staying behind a year) X
Medical: medicine use, diagnoses, glasses/contacts X X X
Allergies X
Use of vitamins and fish oil X
Pubertal Development Scale X X
Alcohol and cigarette use X X
Fish Questionnaire X X X
Centre for Epidemiologic Studies Depression Scale X X X
The Rosenberg Self-Esteem Scale X X X
Motivated Strategies for Learning Questionnaire X X X
Self-reported capsule compliance X X X
Self-reported side effects X X
Self-reported group allocation X
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Mood
Mood is assessed with the Dutch version of the Centre
for Epidemiologic Studies Depression Scale (CES-D),37
a tool sensitive for detecting depressive symptoms and
distinguishing between depressed and non-depressed
individuals.38 39 The CES-D has a high internal reliability
in adolescents (α=0.88).40 The 20 questions question-
naire assesses the presence of depressive symptoms in
the past week. Total sum scores are calculated (range
0-60), with higher scores indicating more depressive
symptoms.
Self-worth/self-esteem
The Rosenberg Self-Esteem Scale (RSE) is a measure of
self-esteem.41 The internal reliability in adolescents is
high (α=0.88)42 43 and construct validity has been
shown.43 This test consists of 10 questions requiring par-
ticipants to indicate their level of agreement with a
series of statements about themselves. Higher scores
indicate a higher self-esteem.
Other measurements
Fish consumption is measured with a short, validated
self-reported questionnaire.44 The pubertal phase is
assessed with the Pubertal Development Scale.45 This
questionnaire assesses the pubertal status of adolescents
by asking to what extent a number of bodily changes
related to puberty are present. Furthermore, nationality,
country of birth of the participants and parents and/or
guardians, language spoken at home, use of medicine,
diagnosis related to learning (eg, ADHD or autism),
allergies, whether the student wears glasses or contact
lenses, whether he/she takes vitamins or ﬁsh oil supple-
ments, drinking and smoking behaviour were assessed
via a questionnaire. Finally, questions about school
career such as whether the participant has ever skipped
or repeated a year are asked. At follow-up, additional
questions with regard to compliance, side effect and
group allocation are asked. For an overview, see table 1.
Biological measurements
Blood analysis
Blood samples are collected with a ﬁnger prick. First, the
ﬁnger of the participants is disinfected with alcohol.
Then a prick with an automated one-time use lancet is
administered at the ﬁngertip after which blood drops are
collected on specially prepared ﬁlter paper. Erythrocyte
fatty acid compositions are analysed according to the
HS-Omega-3 Index methodology as described previ-
ously.29 46 Fatty acid methyl esters are generated by acid
transesteriﬁcation and analysed by gas chromatography
using hydrogen as the carrier gas. Fatty acids are identi-
ﬁed by comparison with a standard mixture of fatty acids.
Results are given as the Omega-3 Index, which is EPA
+DHA expressed as a percentage of total identiﬁed fatty
acids after response factor correction and a correction
for the fact that whole blood was used instead of erythro-
cytes.46 Furthermore, the concentrations of 26 other fatty
acids are determined. The coefﬁcient of variation for
EPA plus DHA typically is 5%. Analyses are quality-
controlled according to DIN ISO 15189.
ApoE4- analyses
Apolipoprotein E (APOE, protein; Apoe, gene) is a
protein which plays an important role in lipid homeosta-
sis. The Apoe gene has four polymorphisms: ε2, ε3 and
ε4. Studies have suggested that ε4 carriers have an
increased risk of late-onset Alzheimer’s disease and
accelerated brain atrophy and that healthy carriers of
the ε4 allele have poorer performance on neuropsycho-
logical tests.47 Furthermore, the effect of an Omega-3
supplement on cognitive performance might be modu-
lated by the presence of ε4 polymorphisms.48 However,
not all studies show an interaction between Apoe status
and cognitive performance.49–51 To elucidate whether
Apoe status interacts with cognitive performance in typic-
ally developing adolescents consuming LCPUFA supple-
mentation, all participants donate 2 mL saliva for the
determination of Apoe status. The analyses of the Apoe
gene will be executed by the departments of Molecular
Genetics and Clinical Genetics of the Maastricht
University Medical Center+, according to the procedure
as described by the Duke University Clinical Molecular
Diagnostics Laboratory.52 Shortly, PCR ampliﬁcation fol-
lowed by Sanger DNA sequencing is used to determine
the genotype of two single nucleotide polymorphisms in
the APOE gene Rs7412 and Rs429 358 and the asso-
ciated APOE genotype. With the participant’s and
parents’ approval (indicated in the informed consent
form), samples will be kept for a maximum of 15 years.
Substudies
All students entering the main study in cohort II were
asked to participate in the sleep study. Pupils of four
schools (due to logistic constraints) in both cohorts were
asked to participate in the eye tracking study.
Participation in both substudies was voluntary and pupils
could participate in the main study regardless of partici-
pation in the substudies.
Substudy I: eye tracking
A subsample of participants (n=33) participated in an
eye tracking study at baseline, 6 months and 12 months.
Eye tracking is a method in which eye movements of par-
ticipants are recorded and can be used to calculate mea-
sures such as number of blinks, number of ﬁxations and
total duration of ﬁxations. Eye movement measures can
help reveal underlying cognitive processes such as
amount of visual processing, what participants are pro-
cessing and the mental effort expended. In Food2Learn,
eye tracking is used to measure the effect of krill oil sup-
plementation on cognitive processing in the form of
visual processing and mental effort (for more informa-
tion, see online supplementary appendix B).
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Substudy II: sleep
In cohort II, a subsample (n=64) is included in a study
investigating the relation between increasing Omega-3
fatty status and sleep quality and duration. Montgomery
et al53 showed that DHA supplementation in children
led to increased sleep duration and fewer waking epi-
sodes per night. Since sufﬁcient sleep is essential for
good health, cognitive performance and school per-
formance,54–56 and insufﬁcient sleep is common in ado-
lescents,57 58 this was included as a substudy. Participants
wore an ActivPAL3 (Paltechnologies, Glasgow, UK)
accelerometer for seven consecutive days at baseline and
seven consecutive days after 12 months of intervention.
With the help of algorithms, ActivPal data can be used
to determine sleep duration and quality. Furthermore,
participants ﬁlled out a diary in which they noted their
bedtime and wake-up time during this week. Finally, they
ﬁlled out the Adolescent Sleep-Wake Scale and the
Adolescent Sleep Hygiene Scale.59
Power calculation
Originally, the sample size calculation was based on a
power of 0.8 and a medium effect size of 0.3 and analysis
of variance (ANOVA) as the analysis method. However,
new insights led to the conclusion that not ANOVA but
a mixed methods analysis would be more appropriate.
The power analyses were thus redone for this. Also, the
new power calculation took into account that there were
multiple measurement moments and that dropout is
possible. Multiple calculation in RMASS software with
standardised input numbers such as an average effect
size of d=0.25 at 6 month follow-up and an equal or 10%
higher effect size at 12 months follow-up and a dropout
of 25% per measurement moment (and thus a total
dropout rate of 43%), an error variation varying from
0.4 to 0.5 and a intercept variation of 0.3 to 0.5 with a
slope variation of 0.0 (ﬁxed effects), showed that
between 183 and 285 participants at baseline should be
sufﬁcient to achieve a power of 0.8.
The power calculation for the sleep substudy sug-
gested that 42 students (21 in the placebo group and 21
in the krill oil group) were sufﬁcient. This number of
students is based on power calculation with a power of
0.8, α=0.05 and the ability to detect a 20 min difference
in sleep duration. For the eye tracking study, no power
calculation was executed. As a study looking at the effect
of krill oil supplementation on cognitive processing mea-
sured with eye tracking had never been executed
before, we did not believe that a reliable power calcula-
tion would be possible.
Data analysis plan
Data are scored by one of the researchers and both D2
and CST tests are checked a second time by another
researcher; 10% of the LDST and digit span are also
checked by a second researcher. All data are entered
twice and any discrepancies between the two data
entries are checked and corrected.
Data analysis will be performed by both the
intention-to-treat procedure and related to the blood
Omega-3 Index. The main effects of the intervention (krill
oil condition in intention-to-treat analyses) and of the
Omega-3 Index on the change from baseline with regard
to cognitive test scores (primary), scores on questionnaires
(secondary) and school grades average (z-score; second-
ary) will be estimated using mixed models that account for
the correlation of repeated measurements within partici-
pants. All estimates will be adjusted for drinking behaviour,
smoking behaviour, level of parental education, age, sex,
body mass index, pubertal status, cohort number and time
trends (baseline, 6 months, 12 months) if necessary.
Furthermore, moderation analyses for sex and APOE
Table 2 Baseline participant characteristics and blood values of selected fatty acids
Participant characteristics
Mean±SD
or N (%) N
Fatty acid
(%wt/wt of total FA)
Mean±SD
(N=261)
Age (years) 14.10±0.49 266 Omega-3 Index 3.83±0.60
Male/female 127/139 (47.7/52.3%) 266 DHA 22:6n-3 2.58±0.49
Smoking no/yes* 239/26 (90.2/9.8%) 265 EPA 20:5n-3 0.39±0.16
BMI 19.92±3.00 248 AA 20:4n-6 11.19±1.25
Underweight, healthy weight, overweight† 28 (10.5%)
182 (68.4%)
39 (14.7%)
Alcohol units per week‡ 0.46±1.77 266 ObA 22:5n-6 0.43±0.10
LPE§ 5.07±1.52 248
*Smoking was defined as anybody who indicated smoking more than 0 cigarettes per week.
†BMI cut-off points: Boys 14 years: underweight <16.40, healthy weight 16.41–22.61, overweight >22.62. Girls 14 years: underweight <16.87,
healthy weight 16.88–23.33, overweight >23.34.
‡A unit of alcohol was defined as one standard glass of an alcohol beverage (ie, a standard drink containing approximately 10g of pure
alcohol).
§Highest level of parental education. Parents/guardians were asked to report the educational level of both parents/guardians. Socioeconomic
status was defined as the highest educational level of the parents/guardians.
AA, arachidonic acid; BMI, body mass index; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FA, fatty acids; LPE, level of parental
education; ObA, osbond acid (also called docosapentaenoic acid).
van der Wurff ISM, et al. BMJ Open 2016;6:e011790. doi:10.1136/bmjopen-2016-011790 7
Open Access
group.bmj.com on July 25, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
status will be executed and, if necessary, separate group
analyses will be executed. Finally, an interaction between
treatment condition and time trend will be used to esti-
mate the difference between the groups regarding time
trend effects. After these analyses, secondary sensitivity
analyses will be executed with treatment adherence
instead of intervention condition. These analyses will also
be run with the subscores of the neuropsychological tests
as outcome variables.
Study monitoring
The study is monitored by the METC, NWO (Dutch
Scientiﬁc Organisation) and the director clinical trials
research and development of AkerBiomarine. The METC
and NWO receive a yearly update. NWO had one site visit.
The director clinical trials research and development visits
the research site twice every year and checks whether all
data are complete and the research is executed according
to Good Clinical Practice. The risk of participating in the
study is judged to be very low as no severe adverse effects
of krill oil are known; however, any adverse effects will be
registered and the METC will be notiﬁed.
Ethics and dissemination
Any major amendments to the protocol will be submit-
ted to the Medical Ethics Committee for approval.
A signed and dated informed consent form is required
from all participants signed by the participant and
parent(s)/guardian(s). All collected data will be linked
to the participant number and only the principal investi-
gators will have access to the non-anonymised data. The
principal investigators have access to all trial data. The
results of the study will be disseminated on group level
to participants and schools. The results of this study will
also be presented at international conferences and pub-
lished in peer-reviewed journals.
Included participants
In total, 288 students provided informed consent. No
blood sample was obtained for four participants. One
participant suffered severe hyperventilation after the
blood sampling and was excluded. Two participants with-
drew their consent before the study started. Fifteen parti-
cipants had an Omega-3 Index of >5%. Thus, 266
participants were included in the supplementation
study; baseline characteristics can be found in table 2.
DISCUSSION
To the best of our knowledge, Food2Learn is the ﬁrst
intervention study in which the inﬂuence of an increase
in the Omega-3 Index due to 1 year of krill oil supple-
mentation on cognition, academic achievement and
behaviour in typically developing adolescents is assessed.
Adolescence is a period of brain maturation in general,
and especially of the higher order cognitive skills, as well
as social and emotional behaviour. Furthermore, adoles-
cence is a critical phase in the school career of students.
All in all, adolescence is an important life period to
study the association between LCPUFAs and cognition/
school performance. Food2Learn is also one of the ﬁrst
studies which has recruited the participants based on a
low Omega-3 Index and which makes use of a persona-
lised dose adjustment based on individual response to
supplementation. The substudies will shed light on areas
that have not received much attention of the LCPUFA
research community yet: sleep quantity and quality and
visual processing and mental workload. The ﬁrst stu-
dents were enrolled in March of 2014; the ﬁnal data will
be collected in August 2016. The ﬁrst longitudinal
results of Food2Learn are expected in the second semes-
ter of 2016.
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